Molecular targeted drugs known as epidermal growth factor receptor tyrosine Kinase Inhibitors (EGFR-TKIs) are regarded as standard first-line therapies for advanced EGFR-mutated lung adenocarcinoma contributing to the reduction of lung cancer mortality [2]. This evidence concerns the gene EGFR and lung carcinoma.